Guidance for Industry (GFI): Electronic Drug Product Reporting for Human Drug Compounding Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act
ICR 201610-0910-005 · OMB 0910-0827 · Historical Active
⚠️ Notice: This information collection may be outdated. More recent filings for OMB 0910-0827 can be found here:
Guidance for Industry (GFI): Electronic Drug Product Reporting for Human Drug Compounding Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act
New collection (Request for a new OMB Control Number)
After an entity has elected to register as an outsourcing facility, it must report information identifying the drugs compounded at the facility in Structured Product Labeling format using FDAâs electronic submissions system. The final guidance addresses new provisions in the Federal Food, Drug, and Cosmetic Act added by the Drug Quality and Security Act and updates reporting instructions for drug compounders that choose to register as outsourcing facilities.
US Code:
21 USC 353b
Name of Law: Federal Food, Drug, and Cosmetic Act; Outsourcing Facilities
On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control number;
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.